daemon@ig.UUCP (11/17/87)
From: CZJ%NIHCU.BITNET@wiscvm.wisc.edu
Attached is the Table of Contents for the NIH Guide to Grants and
Contracts.
Jim Cassatt
------------------------------------------------------------------
Vol. 16, No. 37, November 13, 1987
NOTICE
PHS GRANT APPLICATION FORM 398--REMINDERS....................................1
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)
ADHESION STUDIES OF POLYMER INSULATING COATINGS (RFP).(122/148)..............1
National Institute of Neurological and Communicative Disorders and Stroke
Index: NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE
RESEARCH CENTERS FOR AIDS DEMENTIA AND OTHER
RETROVIRUS-ASSOCIATED NEUROLOGICAL DISORDERS (RFA)..(161/274, 1124/1355)..2
National Institute of Neurological and Communicative Disorders and Stroke
Index: NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE
GENITOURINARY TRACT MANIFESTATIONS OF THE HUMAN IMMUNODEFICIENCY
VIRUS (HIV) (RFA)..(277/387, 1359/1664)...................................3
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES
EFFECTS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS ON
THE KIDNEY, AND IN DIALYSIS AND RENAL TRANSPLANT
PATIENTS (RFA)...(401/542, 1668/2029).....................................5
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES AND DIGESTIVE AND KIDNEY DISEASES
BIOMEDICAL RESEARCH SUPPORT SHARED INSTRUMENTATION GRANTS..(545/733).........6
Division of Research Resources
Index: RESEARCH RESOURCES
BEHAVIORAL MECHANISMS AND CAUSES OF CHILDHOOD INJURY(RFA)(736/818, 2033/2276) 9
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT
SPECIALIZED CARIES RESEARCH CENTERS (RFA).(821/913, 2278/2562)...............10
National Institute of Dental Research
Index: DENTAL HEALTH
ONGOING PROGRAM ANNOUNCEMENTS
HEALTH PROMOTION RESEARCH UNDERLYING NURSING PRACTICE (PA)...(919/976).......11
National Center for Nursing Research
Index: NURSING RESEARCH
BIOLOGICAL DETERMINANTS OF ALCOHOL CONSUMPTION (PA)..(979/1100)..............12
National Institute on Alcohol Abuse and Alcoholism
Index: ALCOHOL ABUSE AND ALCOHOLISM
NOTICE
PHS GRANT APPLICATION FORM 398--REMINDERS
P.T. 34; K.W. 0710030, 1014002
National Institutes of Health
The newly revised form PHS 398 (dated 9/86) must be used by all NRSA
Institutional Training Grant applicants starting with the January 10, 1988
receipt date, and by all research grant applicants starting with the February
1, 1988 receipt date. The page limitations indicated in the instructions for
the 9/86 revision must be observed. PLEASE NOTE THAT ANY APPLICATION
SUBMITTED ON ANY VERSION OF THE PHS 398 OTHER THAN THE 9/86 REVISION WILL BE
RETURNED WITHOUT REVIEW, AS WILL APPLICATIONS THAT EXCEED THE PAGE LIMITS
SPECIFIED IN THE PHS 398 INSTRUCTIONS OR SUPPLEMENTAL INSTRUCTIONS PERTAINING
TO A PARTICULAR PROGRAM.
It is important to submit legible copies of the application. The original
pages of the PHS 398 form, printed in orange ink, should be used. However, if
these pages are not reproducible by any copying machine available to your
institution, you may substitute the draft pages of the form (which are in
black ink) after deleting the words "Remove and Use for Draft Copy" in the
margin. DO NOT SUBSTITUTE THE 5/82 VERSION OF THE PHS 398. An application
will be considered incomplete and returned if the original and all copies are
not legible.
------------------------------------------------------------------
RESEARCH CENTERS FOR AIDS DEMENTIA AND OTHER
RETROVIRUS-ASSOCIATED NEUROLOGICAL DISORDERS
RFA AVAILABLE: 88-NS-07
P.T. 04; K.W. 0715120, 0710085, 1003002, 0785110, 0414000
National Institute of Neurological and Communicative Disorders and Stroke
Application Receipt Date: February 12, 1988
The National Institute of Neurological and Communicative Disorders and Stroke
(NINCDS) announces the availability of an RFA for the establishment of
research centers for the investigation and elucidation of the etiology and
pathogenesis, natural history, epidemiology, pathology, definition of the
diagnostic criteria, and prevention and therapy of AIDS dementia and other
retrovirus-associated neurological syndromes. Proposals focusing on AIDS
dementia and encephalomyelopathy in children and infants are particularly
encouraged.
While the principal stimulus for establishment of these centers is concern for
the involvement of the central nervous system in AIDS, appropriate studies in
relevant fundamental neurobiological areas will be acceptable within the
center's mission, e.g., basis for the predilection of some retroviruses for
the nervous system, as well as studies of retrovirus-associated neurological
diseases, other than AIDS, such as tropical spastic paraparesis in humans and
visna in animals.
The number of people, including children and infants, affected by the AIDS
retrovirus, HIV, is growing, and the associated neurological syndromes are
recognized with increasing frequency. Neurological involvement may be
apparent before severe immunodeficiency is recognized. The neurological
disorders associated with AIDS are of particular concern to the NINCDS.
Dementia is one of the more common and devastating neurological complications
of AIDS. As many as 60 percent of patients with AIDS may develop dementia
that cannot be attributed to opportunistic infections. The dementia may occur
at any stage; it is often manifested very early in the clinical course of the
illness.
Other neurological manifestations associated with HIV infection are spastic
paraplegia and ataxia, sensory and motor neuropathies, multiple
mononeuropathies, developmental abnormalities in children with loss of
cognitive ability and progressive long-tract signs, and a dysmorphic syndrome
due to intrauterine infection with the HIV.
The clinical features, course, and pathology of these conditions require
elucidation and clarification. An understanding of the etiologies and
pathogeneses may provide a rational basis for the development and evaluation
of prophylactic and therapeutic strategies.
Multidisciplinary approaches are encouraged. Investigations appropriate to
the RFA are broad and limited only by the creativity and ability of the
applicants to exploit leads from basic studies in virology, molecular
neurobiology, immunology, biochemistry, neuropathology, and clinical
neurology. Fundamental scientific approaches consonant with the RFA may range
from investigations of the peculiarities that predispose to persistent
retrovirus infection in the central nervous system to the effects of the
dysimmune state on the developing and mature nervous system. Studies leading
to the identification and development of animal models of retrovirus infection
with predilection for the mature and immature central and peripheral nervous
systems are particularly solicited.
The NINCDS anticipates establishing up to four research centers, each for five
years. Awards for these centers will depend upon availability of funds. We
anticipate supporting centers with major thrust on the neurological aspects of
AIDS in children, and in adults, as well as on the clinical neuroscience of
other retroviral diseases in man and in animal models.
To qualify for consideration, an appropriate population of clinically
well-defined patients with AIDS and ARC sufficient in number to meet the
objectives of the research plan is essential. A well-established
neuropathological research program and a broad, fundamental neuroscience
capability are prerequisites for successful applications.
Any United States academic medical center, school of public health, research
institution, profit-making organization, or consortium of cooperating
2
institutions may submit a proposal. Applicants must demonstrate the ability
to marshall the requisite expertise needed for all functions of the research
plan, including neurological, neuropsychological, and behavioral assessment of
AIDS patients; neuropathological confirmation of diagnosis; biometry,
epidemiology, and clinical data management; and fundamental neurovirological
and immunological research. Prospective applicants are encouraged to consult
with the staff of the Division of Demyelinating, Atrophic, and Dementing
Disorders early in the planning stage.
A copy of the complete RFA, which provides background information, research
goals and scope, terms and conditions, review procedures and criteria, and the
NINCDS guidelines for preparation and submission of clinical research center
proposals may be obtained by contacting the program administrator:
Dr. A.P. Kerza-Kwiatecki
Program Administrator
Division of Dmeyelinating, Atrophic, and Dementing Disorders
Federal Building, Room 702
National Institute of Neurological and Communicative Disorders and Stroke
Bethesda, Maryland 20892
The National Institute of Mental Health also supports research centers on the
assessment of the central nervous system effects of the AIDS virus, such as
dementia, cognitive impairment, and neuropsychiatric disorders. A more
detailed announcement of NIMH interests will be published in the near future.
Potential applicants should contact:
Dr. Ellen Simon Stover
Deputy Director, Division of Basic Sciences
National Institute of Mental Health
Room 11-103, Parklawn Building
5600 Fishers Lane
Rockville, Maryland 20857
Telephone: (301) 443-3563
GENITOURINARY TRACT MANIFESTATIONS OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV)
RFA AVAILABLE: 88-DK-02
P.T. 34; K.W. 0715120, 0715125, 0705075, 1002045
National Institute of Diabetes and Digestive and Kidney Diseases
Application receipt date: February 10, 1988
The Division of Kidney, Urologic and Hematologic Diseases (DKUHD) of the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
invites grant applications for support of research on the effects of
infections with the Human Immunodeficiency Viruses (HIV) on the genitourinary
(GU) tract.
Significant progress has been made in understanding the molecular biology and
the clinical presentations of HIV infections. It has also been established
that the genitourinary tract plays a major role in the transmission of the
virus. Further work is needed to better understand the behavior of the virus
in the GU tract, the site(s) of virus replication, and factors influencing
transmission of the virus from an individual to another.
BACKGROUND
Since first diagnosed in 1978, the incidence of AIDS has increased
substantially in the United States, and many other parts of the world. The
causative agent, the human immunodeficiency virus (HIV), has been shown to
have a high predilection for the T lymphocyte. In addition to blood, semen of
infected individuals has been demonstrated as a very effective vehicle for
transmission. The T lymphocyte has been proposed as the agent responsible for
transporting the virus throughout the body, and probably from host to host.
Although the T lymphocyte in the semen may be an effective means of
transmission of the virus, other mechanisms are possible.
The purpose of this initiative is to seek proposals which deal with the HIV
infections in the GU tract, the specific organs and cells in which the virus
resides and/or replicates, and the mechanisms of transmission from host to
host. Particular encouragement is offered to investigators well-trained in
pertinent technologies who currently may be pursuing other research interest.
3
RESEARCH OBJECTIVES
The GU tract is a focal point in the transmission of the HIV from host to
host. Although the mode of transmission from the male is proposed to be via
the semen, the mechanism from female to male is not well-understood. It is
also unclear whether the virus in the GU tract resides and replicates in cells
other than the T lymphocytes. Nor has there been a clear definition of the
specific organs in the GU tract where the virus resides and/or replicates.
Conditions in the GU tract that promote or hinder transmission of the virus
need to be explored. Finally, very little is known of the effect of specific
therapy, directed against the virus, such as AZT, on the structure and
functions of organs and cells of the GU tract. A major objective of this
initiative is to encourage collaboration between individuals in the basic and
applied fields of medicine to study the needed mechanisms of viral replication
and transmission through the GU tract.
APPLICATION AND REVIEW PROCEDURES
Applications in response to this RFA will be reviewed for scientific and
technical merit by an initial review group which will be convened by the
Division of Extramural Activities, NIDDK, solely to review these applications.
Upon receipt, applications will be evaluated for their responsiveness to the
objectives of the RFA. If an application is judged unresponsive at this
stage, the applicant will be contacted and given the opportunity to withdraw
the application or have it considered for the regular research grant program
of the NIH. Should the proposal submitted in response to the RFA be
substantially similar to a research grant application already under
consideration by the NIH, the applicant will be asked to withdraw either
application. Simultaneous submission of identical applications will not be
allowed.
Funding decisions will be based on recommendations by the Initial Review Group
and by the National Diabetes and Digestive and Kidney Diseases Advisory
Council, and relevance to the Objectives and Scope of the RFA. Applicants
should request a start date of September 30, 1988.
The support mechanism for this program will be the traditional, individual,
research-project grants (RO1s) only. Current plans for Fiscal Year 1988
include $3.0 million for the total (direct and indirect) costs of this
program. However, the funding of applications submitted in response to this
RFA is contingent on the actual availability of funds and receipt of
applications deemed worthy of support by the accepted NIH peer review
procedure. It is anticipated that 15 - 20 grants will be awarded, for up to 5
years, under this program. The specific amount to be funded will depend on
the merit and scope of the applications received.
Copies of the complete RFA may be obtained from :
Lawrence Agodoa, M.D.
Director, Clinical Studies
DKUHD, NIDDK
National Institutes of Health
Westwood Building, Room 625
Bethesda, Maryland 20892
Telephone (301) 496 7571
Prospective applicants are asked to submit a letter of intent no later than
January 15, 1988. The Institute requests such letters for the purpose of
ascertaining the number and types of applications to be reviewed. Such
letters are not required, are not binding, and do not enter into the review of
the application.
Applications should be submitted on PHS Form 398 (revised Sept. 1986). The
RFA label available in the 9/86 Revision of Application of Form 398 must be
affixed to the bottom of the face page. Failure to use this label could
result in delayed processing of your application such that it may not reach
the Review Committee in time for review.
------------------------------------------------------------------
BIOMEDICAL RESEARCH SUPPORT SHARED INSTRUMENTATION GRANTS
P.T. 34; K.W. 1014001, 0780005
Division of Research Resources
Application Receipt Date: February 23, 1988
BACKGROUND
The Division of Research Resources (DRR) is continuing its competitive
Biomedical Research Support (BRS) Shared Instrumentation Grant (SIG) Program
initiated in Fiscal Year 1982. The program was established in recognition of
6
the long-standing need in the biomedical research community to technological
advances in instrumentation and the rapid cope with rapid rate of obsolescence
of existing equipment. The objective of the program is to make available, to
institutions with a high concentration of PHS-supported biomedical
investigators, research instruments which can only be justified on a
shared-use basis and for which meritorious research projects are described.
An eligible institution may submit more than one application for different
instrumentation for the February 23, 1988 deadline. However, if multiple
applications are submitted for similar instrumentation from one or more
eligible components of an institution, then documentation from a high
administrative official must be provided, stating that the multiple
applications are a coordinated institutional resource plan, not an unintended
duplication.
RESEARCH GOALS AND SCOPE
This program is designed to meet the special problem of acquisition and
updating of expensive shared-use instruments which are not generally available
through other PHS mechanisms, such as the regular research project, program
project and center grant programs, the Biomedical Research Technology Grant
Program, or the Biomedical Research Support (BRS) Grant Program. Proposals
for the development of new instrumentation will not be considered.
ELIGIBILITY
The BRS Shared Instrumentation Grant Program is a subprogram of the BRS Grant
Program of DRR. Awards are made under the authority of the BRS program and
are made to institutions only, not to individuals. Therefore, eligibility is
limited to institutions which receive a BRS grant award. Awards are
contingent on the availability of funds.
MECHANISM OF SUPPORT
BRS Shared Instrumentation Grants provide support for expensive
state-of-the-art instruments utilized in both basic and clinical research.
Applications are limited to instruments that cost at least $100,000 per
instrument or system. The maximum award is $400,000. Types of
instrumentation supported include, but are not limited to, nuclear magnetic
resonance systems, electron microscopes, mass spectrometers, protein
sequencer/amino acid analyzers and cell sorters. Support will not be provided
for general purpose equipment or purely instructional equipment. Proposals
for "stand alone" computer systems will only be considered if the instrumemnt
is solely dedicated to the research needs of a broad community of
PHS-supported investigators.
Awards will be made for the direct costs of the acquisition of new, or the
updating of existing, research instruments. The institution must meet those
costs (not covered in the normal purchase price) required to place the
instrumentation in operational order as well as the maintenance, support
personnel and service costs associated with maximum utilization of the
instrument. There is no upper limit on the cost of the instrument, but the
maximum award is $400,000. Grants will be awarded for a period of one year
and are not renewable. Supplemental applications will not be accepted. The
program does not provide indirect costs or support for construction or
alterations and renovations. Cost sharing is not required. If the amount of
funds requested does not cover the total cost of the instrument, the
application should describe the proposed source(s) of funding for the balance
of the cost of the instrument. Documentation of the availability of the
remainder of the funding, signed by an appropriate institutional official,
must be presented to DRR prior to the issuance of an award.
A major user group of three or more investigators should be identified. A
minimum of three major users must have PHS peer-reviewed research support at
the time of the award. The application must show a clear need for the
instrumentation by projects supported by multiple PHS research awards and
demonstrate that these projects will require at least 75% of the total usage
of the instrument. Major users can be individual researchers, or a group of
investigators within the same department or from several departments at the
applicant institution. PHS extramural awardees from other institutions may
also be included.
If the major user group does not require total usage of the instrument, access
to the instrument can be made available to other users upon the advice of the
internal advisory committee. These users need not be PHS awardees, but
priority should be given to PHS-supported scientists engaged in biomedical
research.
7
ADMINISTRATIVE ARRANGEMENTS
Each applicant institution must propose a Principal Investigator who can
assume administrative/scientific oversight responsibility for the
instrumentation requested. An internal advisory committee to assist in this
responsibility should also be utilized. The Principal Investigator and the
advisory group are responsible for the development of guidelines for shared
use of the instrument, for preparation of all reports required by the NIH, for
relocation of the instrument within the grantee institution if the major user
group is significantly altered and for continued support for the maximum
utilization and maintenance of the instrument in the post-award period.
A plan should be proposed for the day-to-day management of the instrument
including designation of a qualified individual to supervise the operation of
the instrument and to provide technical expertise to the users. Specific
plans for sharing arrangements and for monitoring the use of the instrument
should be described.
If a grant award is made, a final progress report will be required which
describes the use of the instrument, listing all users, and indicating the
value of the instrumentation to the research of the major users and to the
institution as a whole. This report is due within 90 days following the end
of the project period.
REVIEW PROCEDURES AND CRITERIA
Applications are reviewed by specially convened initial review groups of the
Division of Research Grants (DRG) for scientific and technical merit and for
program considerations by the National Advisory Research Resources Council of
the DRR. Funding decisions are the responsibility of the DRR and will not be
made prior to November 15, 1988.
Criteria for review of applications include the following:
o The extent to which an award for the specific instrument would meet
the scientific needs and enhance the planned research endeavors of
the major users by providing an instrument that is unavailable or
to which availability is highly limited.
o The availability and commitment of the appropriate technical
expertise within the major user group or the institution for use of
the instrumentation.
o The adequacy of the organizational plan and the internal advisory
committee for administration of the grant including sharing
arrangements for use of the instrument.
o The benefit of the proposed instrument to the overall research
community it will serve.
METHOD OF APPLYING
Copies of a more detailed announcement are being mailed to Program Directors
of BRS grants and to sponsored program offices at all institutions currently
receiving BRS grants. Interested investigators should obtain the complete
announcement prior to preparing an application.
Applications must be received by February 23, 1988. Applications received
after this date will not be accepted for review in this competition. The
original and four copies should be sent to:
Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
5333 Westbard Avenue
Bethesda, Maryland 20892**
Two copies of the application and one copy of any appendix material should be
addressed to:
Biomedical Research Support Program
Division of Research Resources
National Institutes of Health
Building 31 - Room 5B23
9000 Rockville Pike
Bethesda, Maryland 20892
8
If appendix material is submitted, four collated sets must be included with
the application package to the Division of Research Grants.
Inquiries should be directed to the Biomedical Research Support Program Office
at (301) 496-6743.
This program is described in the Catalog of Federal Domestic Assistance number
13.337, Biomedical Research Support. Awards will be made under the authority
of the Public Health Service Act, Section 301 (Public Law 78-410, as amended;
42 USC 241) and administered under PHS grant policies and Federal Regulations
42 CFR Part 52 and 42 CFR Part 74. This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency Review.